Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anthera Raising $25M Through Public Offering

This article was originally published in Scrip

Executive Summary

Hayward, California-based biotech Anthera Pharmaceuticals announced on 18 March that it priced 5.6m shares at $4.50 per share in a public offering underwritten by Piper Jaffray & Co. Anthera expects to bring in $25m from the offering, before expenses, and anticipates a closing data of 23 March. Piper Jaffray has the option of purchasing another 833,333 shares. The money will be used for development and general expenses. The company is conducting a Phase III study of blisibimod, a selective inhibitor of B-cell activating factor (BAFF) for the treatment of lupus, despite underwhelming results in a Phase IIb study (scripintelligence.com, 11 February 2015). The company also has a non-porcine pancreatic enzyme replacement therapy (PERT) that it acquired from Eli Lilly in development (scripintelligence.com, 15 July 2014).

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028150

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel